Published Date: 13 Mar 2023
NEW DELHI: Jaipur-based orthopedic surgeon arrested for neglecting plastic surgery on burn patient...
Read Full NewsIn a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
1.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
2.
BlurryScope: A compact, AI-powered microscope for rapid, cost-effective cancer scoring
3.
A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.
4.
A large study found that monolayers were superior in detecting cancer.
5.
High levels of traumatic stress found in caregivers of adult cancer patients
1.
The Power of Salt Tablets: Unlocking Health Benefits Beyond Sodium
2.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
3.
Unraveling the Complexities of Embryonal Carcinoma: A New Hope for Treatment
4.
The Latest Research on Chronic Granulomatous Disease and Promising New Treatments
5.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
3.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation